Cargando…
Simultaneous development of zanubrutinib in the USA and China
Zanubrutinib was recently granted expedited approval by the USA and Chinese drug regulatory authorities for the treatment of mantle cell lymphoma, thus becoming the first investigational new drug discovered in China to achieve simultaneous development in both countries. Here, we provide an overview...
Autores principales: | Li, Guanqiao, Liu, Xiaozhen, Chen, Xiaoyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351534/ https://www.ncbi.nlm.nih.gov/pubmed/32651571 http://dx.doi.org/10.1038/s41571-020-0414-y |
Ejemplares similares
-
Offline: USA versus China—the growing insanity of our times
por: Horton, Richard
Publicado: (2021) -
The cost of preventable disease in the USA
por: Galea, Sandro, et al.
Publicado: (2020) -
The pandemic legacy of antimicrobial resistance in the USA
por: Patel, Jay, et al.
Publicado: (2022) -
Addressing the void: firearm injury prevention in the USA
por: Lee, Lois K, et al.
Publicado: (2022) -
Infectious diseases compensation in the USA: the relative value
por: El Helou, Guy, et al.
Publicado: (2022)